Status:
COMPLETED
Efficacy and Safety of Ginkgo Biloba Extract in Mild Cognitive Impairment and Cerebrovascular Insufficiency
Lead Sponsor:
Milsing d.o.o.
Conditions:
Mild Cognitive Impairment
Cerebrovascular Insufficiency
Eligibility:
All Genders
50+ years
Phase:
PHASE4
Brief Summary
The purpose of the study is to determine weather Ginkgo biloba standardized extract (24% ginkoflavonoglicozides and 6% terpenes) is effective in treatment of cognitive and concentration impairment
Detailed Description
Inclusion criteria is cerebrovascular insufficiency MNSE\>20. 90 patients are divided into three groups randomly. First group is being administered 120 mg ginkgo biloba extract, second group 60 mg of ...
Eligibility Criteria
Inclusion
- cerebrovascular insufficiency and mild cognitive disorder (MMSE=20-28)
Exclusion
- pregnancy
- cognitive disorder caused by psychological, metabolic endocrine nutritional and heart disorder
- alcohol or drug abuse
Key Trial Info
Start Date :
May 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2010
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT00446485
Start Date
May 1 2007
End Date
April 1 2010
Last Update
September 28 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Department of Neurology, Sestre milosrdnice University Hospital, Vinogradska 29
Zagreb, Croatia, 10000